Tag: mental health is health

  • 🧪 Exciting Breakthrough in Cannabis Use Disorder Treatment!

    🧪 Exciting Breakthrough in Cannabis Use Disorder Treatment!

    A recent Phase 2b clinical trial has shown that PP-01, an investigational therapy by PleoPharma, significantly reduces cannabis withdrawal symptoms in individuals with Cannabis Use Disorder (CUD). The study demonstrated a clear dose-response relationship, with the highest dose yielding clinically meaningful results (p=0.02). Importantly, PP-01 was well-tolerated with no safety concerns.

    Recognizing the urgent need for effective treatments, the FDA has granted Fast Track designation to PP-01, expediting its development and review process. This brings hope to the approximately 19.2 million Americans affected by CUD, as there are currently no FDA-approved medications for cannabis withdrawal.

    PP-01 works by targeting suppressed CB1 receptors and neurotransmitter dysregulation in the brain’s reward pathway, offering a novel approach to mitigating withdrawal symptoms. As it enters Phase 3 trials, PP-01 holds promise as a first-in-class treatment for those seeking to overcome cannabis dependence.

  • 🚨 Health Care is Under Attack

    🚨 Health Care is Under Attack

    Our patients are under attack. Our oath to do no harm is under attack. Health care is under attack.

    Last week, the U.S. House of Representatives passed a budget resolution that could slash $880 billion from Medicaid—a devastating blow that would strip 15.9 million people of health coverage. That’s 1 in 5 of your friends, neighbors, and patients.

    📉 Who will suffer most?
    🔹 Children
    🔹 The elderly
    🔹 People with disabilities
    🔹 Those living in poverty

    These are the people we serve every day

    We cannot stand by as essential care is ripped away from the most vulnerable. This is not a red or blue issue —this is a people issue.

    🩺 If you’re a healthcare professional, patient, or advocate, now is the time to speak up. Join us in the fight to protect Medicaid and ensure no one is left behind.

  • 🌿 CBD for Psychosis? A Landmark Trial is Underway 🧠

    🌿 CBD for Psychosis? A Landmark Trial is Underway 🧠

    A major new study—the Stratification and Treatment in Early Psychosis (STEP) trial—is set to investigate CBD as a potential treatment for psychosis on a larger scale than ever before. Led by Philip McGuire, MD, professor of psychiatry at Oxford University, STEP will involve 1,000 participants across 30 sites in 10 countries 🌍, making it one of the most ambitious trials of its kind.

    🔬 Why it matters:
    ✅ CBD has shown promise in early studies for psychosis, but large-scale evidence is needed.
    ✅ STEP will combine three smaller trials to explore effectiveness, biomarkers, and precision treatment approaches.
    ✅ Nature Medicine named it one of 11 studies that will shape medicine in 2025.

    🚀 Could CBD redefine psychosis treatment? The results could change the landscape of psychiatric care. Stay tuned!

  • 🧠 Microplastics in the Brain: A Rising Concern for Mental Health? 🧠

    🧠 Microplastics in the Brain: A Rising Concern for Mental Health? 🧠

    New research reveals that microplastics and nanoplastics (MNPs) have been accumulating in the human brain at increasing levels from 2016 to 2024—and in higher concentrations than in other organs. 😳

    What does this mean for mental health? While the psychiatric implications are still being explored, potential concerns include:
    🔬 Neuroinflammation – A known factor in mood and cognitive disorders.
    🧩 Blood-brain barrier disruption – Could impact neurotransmission.
    ⚡ Oxidative stress & toxicity – Possible links to neurodegenerative and psychiatric conditions.

    🚨 Big picture: We need more research, but growing evidence suggests environmental factors like MNP exposure could play a role in brain health and psychiatric disorders.

  • 🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

    🚨 AI Predicting Schizophrenia & Bipolar Disorder? Not So Fast…

    A new study trained an AI model on 24,000+ electronic health records (EHRs) to predict whether a patient would develop schizophrenia or bipolar disorder. The results? 🤔

    🔍 The XGBoost machine learning model showed better performance for schizophrenia than bipolar disorder.
    📊 It achieved an AUC of 0.70 on training data and 0.64 on the test set.
    ⚠️ But here’s the catch: despite 96.3% specificity, the model’s sensitivity was just 9.3%, meaning it missed the vast majority of cases.

    💡 Bottom Line: AI in psychiatry is promising, but we’re not at the point where a model like this could reliably flag patients at risk. High specificity sounds great—until you realize the trade-off is missing 90%+ of those who actually transition to schizophrenia or bipolar disorder.

    Will future AI tools get better at predicting these life-altering conditions? Time (and data) will tell. ⏳

  • The Pill Won’t Solve It All 💊🚫

    The Pill Won’t Solve It All 💊🚫

    When every problem you face has been treated exclusively by a pill, you start to believe that the answer to all your struggles lies in finding the right one. 🤔💡

    With this mindset, you will never be well. 🧠❌

    It’s no different than someone searching for the perfect car 🚗 or the dream home 🏡 to fix their life. Sure, it might bring temporary relief, but in the end, it steals your power, leaving your happiness dependent on external factors you can’t control. 🎭🔗

    True healing starts when you reclaim your own agency. 💪🔥

  • Semaglutide (#Ozempic / #Wegovy) Reduced Alcohol & Nicotine Use in a First-of-Its-Kind RCT

    Semaglutide (#Ozempic / #Wegovy) Reduced Alcohol & Nicotine Use in a First-of-Its-Kind RCT

    📉 In a randomized trial with 48 patients diagnosed with #AlcoholUseDisorder, semaglutide significantly lowered alcohol intake in a controlled lab setting.

    🚬 Interestingly, nicotine consumption also decreased.

    💉 Low doses (0.25-1 mg/week) were used over 9 weeks—much lower than standard obesity or diabetes dosing.

    🔬 More research is needed, but this adds to growing evidence that GLP-1 agonists may impact addictive behaviors.

    Link to article: https://pubmed.ncbi.nlm.nih.gov/39937469/

  • 📌 CANMAT Guidelines for Depression: 2023 Update

    📌 CANMAT Guidelines for Depression: 2023 Update

    The Canadian Network for Mood and Anxiety Treatments (CANMAT) released updated guidelines in 2023 for the management of Major Depressive Disorder (MDD), reflecting recent advancements in the field.

    Key Updates in the 2023 CANMAT Guidelines:

    1. Personalized Care Approach:
      • Emphasis on shared decision-making, considering patient values, preferences, and treatment history to tailor individualized treatment plans.
    2. Updated Treatment Recommendations:
      • Psychological Therapies: Continued endorsement of therapies like Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy (IPT) for mild to moderate depression.
      • Pharmacological Treatments: Introduction of newer antidepressants and updated recommendations based on recent evidence.
      • Neuromodulation: Expanded guidance on treatments such as Transcranial Magnetic Stimulation (TMS)and Electroconvulsive Therapy (ECT), especially for treatment-resistant cases.
    3. Lifestyle and Complementary Interventions:
      • Recognition of the role of exercisenutrition, and sleep in managing depression.
      • Evaluation of complementary and alternative medicine approaches, providing guidance on their efficacy and safety.
    4. Digital Health:
      • Assessment of digital interventions, including online therapy platforms and mobile applications, as supplementary tools in treatment plans.
    5. Management of Inadequate Response:
      • Strategies for addressing partial or non-response to initial treatments, including augmentation and combination therapies.

    These updates underscore the importance of a collaborative and individualized approach in managing MDD, integrating the latest evidence to optimize patient outcomes.

    For a comprehensive overview, refer to the full publication: 

    pubmed.ncbi.nlm.nih.gov

  • 💊 Antidepressants Prescriptions in the U.S. a Balanced Approach? 🤔

    💊 Antidepressants Prescriptions in the U.S. a Balanced Approach? 🤔

    Evidence Supporting Overprescription

    1. Prescribing Without Meeting Diagnostic Criteria
      • 2011 study published in Health Affairs found that only 38.4% of patients prescribed antidepressants met criteria for major depressive disorder (MDD), based on the National Ambulatory Medical Care Survey. Many prescriptions were given for milder depressive symptoms or anxiety disorders, suggesting potential overprescription.
      • Subclinical Depression: Some prescriptions were issued for symptoms that did not meet the diagnostic threshold for any psychiatric disorder.
    2. Primary Care Prescribing Patterns
      • Antidepressants are frequently prescribed in primary care settings, where diagnostic accuracy may be lower than in psychiatric settings.
      • 2020 review in JAMA Internal Medicine highlighted that primary care physicians write 79% of antidepressant prescriptions in the U.S., and these are often issued without consultation with a mental health professional.
    3. Off-Label Use
      • 2016 study in JAMA Psychiatry found that 30% of antidepressant prescriptions are for off-label indications like insomnia, chronic pain, or fatigue, despite limited evidence supporting their efficacy for many of these uses.
    4. Prolonged Use
      • Many individuals take antidepressants for extended periods without regular reassessment. A 2019 study in The British Journal of Psychiatry noted that long-term antidepressant use often continues without clear ongoing benefit, raising questions about whether prescriptions are monitored effectively.

    Evidence Suggesting Appropriate or Underprescription

    1. Untreated Mental Illness
      • The World Health Organization (WHO) estimates that nearly 50% of individuals with depression in high-income countries, including the U.S., do not receive treatment.
      • 2017 study in JAMA Psychiatry found that many individuals with severe depressive symptoms go untreated, particularly in low-income or minority populations.
    2. Misperceptions of Overprescription
      • 2020 meta-analysis in The Lancet Psychiatry showed that antidepressants are highly effective for moderate-to-severe depression, and their increased use could reflect improved treatment of these conditions rather than overprescription.
      • Increased public awareness of mental health has led to more people seeking care, which may explain higher prescription rates.
    3. Use in Non-Psychiatric Disorders
      • Antidepressants, particularly SSRIs and SNRIs, are evidence-based treatments for anxiety disorders, PTSD, OCD, and some chronic pain conditions. Their prescription for these conditions might be misinterpreted as “overprescription.”

    Balancing Perspectives

    The evidence suggests a mixed picture:

    • On one hand, antidepressants are sometimes prescribed without meeting diagnostic criteria or for off-label uses with weak supporting evidence.
    • On the other hand, a significant proportion of individuals with moderate-to-severe depression or anxiety remain untreated, indicating possible under prescription in certain populations.

    Scientific Consensus

    The issue may stem less from overprescription overall and more from suboptimal prescribing practices, including:

    • Prescribing antidepressants where psychotherapy or other treatments might be more appropriate.
    • Inadequate follow-up or reassessment of long-term users.
    • Limited mental health training for primary care providers, who are often the frontline prescribers.
  • Narcissistic Personality Disorder: Two Faces Explained

    Narcissistic Personality Disorder: Two Faces Explained

    The key difference between vulnerable narcissistic personality disorder (NPD) and grandiose NPD lies in how the narcissistic traits are expressed and how the person copes with feelings of inadequacy and low self-esteem. Both fall under the umbrella of narcissistic personality disorder, but they represent different presentations:

    Grandiose Narcissism

    • Core Traits:
      • Overt self-importance and entitlement.
      • A strong sense of superiority and belief in their own greatness.
      • Craving admiration and validation from others.
      • Often charismatic, confident, and socially dominant.
    • Defense Mechanisms:
      • Rely on denial and externalizing blame to avoid feeling vulnerable.
      • Tend to dismiss or belittle others’ opinions if they conflict with their own.
    • Interpersonal Behavior:
      • Exploitative in relationships, using others to bolster their self-esteem.
      • Seek out positions of power or visibility to maintain their inflated self-image.
    • Emotional Regulation:
      • Typically outwardly composed and unbothered, though they may become aggressive or vindictive if their self-image is challenged.

    Vulnerable Narcissism

    • Core Traits:
      • Feelings of inadequacy, hypersensitivity to criticism, and low self-esteem.
      • A covert sense of entitlement—believing they deserve admiration but fearing they won’t get it.
      • A façade of humility or introversion, masking deep insecurities.
    • Defense Mechanisms:
      • Use avoidance and withdrawal to protect themselves from perceived rejection or failure.
      • Internalize blame and self-doubt, leading to cycles of shame and self-criticism.
    • Interpersonal Behavior:
      • Appear shy, reserved, or socially anxious, but they harbor fantasies of being special or recognized.
      • May oscillate between needing reassurance and distancing themselves from others out of fear of being hurt.
    • Emotional Regulation:
      • Prone to depression, anxiety, and mood swings.
      • Vulnerable to feelings of emptiness and envy of others’ success.

    Clinical Distinction

    • While grandiose narcissists may seem outwardly self-assured and dominant, vulnerable narcissists are more likely to present with symptoms resembling mood or anxiety disorders, often masking their narcissistic traits.
    • Both types share a fragile self-esteem at their core but manifest it in opposite ways: grandiose types inflate their self-image, while vulnerable types retreat into themselves.

    Grandiose Narcissism in a Clinical Setting

    Case Example:

    • Presentation: A 45-year-old CEO attends therapy after his spouse threatens divorce, citing his arrogance and lack of empathy. He describes the problem as “Everyone just misunderstands how hard it is to be as driven and successful as me.”
    • Behavior in Session:
      • Dominates conversations, dismisses the therapist’s insights, and subtly challenges their expertise.
      • Boasts about his achievements, financial success, and social status but avoids discussing emotional issues or personal failures.
      • Minimizes his spouse’s complaints as “overreactions,” viewing them as jealous or ungrateful.
    • Underlying Issues:
      • Although he appears self-confident, his grandiosity masks deep fears of failure and inadequacy.
      • His need for admiration and his inability to tolerate criticism create interpersonal conflict.
    • Therapeutic Challenge:
      • Establishing rapport while gently confronting his defensiveness.
      • Helping him acknowledge and address the vulnerability underlying his grandiosity without triggering a withdrawal or rage response.

    Vulnerable Narcissism in a Clinical Setting

    Case Example:

    • Presentation: A 30-year-old graduate student seeks therapy for persistent depression and social anxiety. She describes herself as “a failure” and avoids academic conferences because she feels “everyone there is smarter and more talented.”
    • Behavior in Session:
      • Initially shy and reserved but gradually reveals fantasies of being recognized as brilliant and exceptional in her field.
      • Complains about colleagues receiving awards, feeling envious and deeply resentful, but also guilty for having those feelings.
      • Struggles to accept praise, dismissing it as insincere or undeserved, and reacts strongly to perceived slights or criticism.
    • Underlying Issues:
      • She feels torn between craving recognition and fearing rejection.
      • Her self-esteem depends heavily on external validation, but she avoids situations where she might fail or be criticized.
    • Therapeutic Challenge:
      • Helping her tolerate and process feelings of inadequacy without retreating into shame or avoidance.
      • Building her sense of self-worth independent of external achievements or comparisons.

    Comparison:

    1. Interpersonal Dynamics:
      • Grandiose narcissists demand validation and admiration from others; vulnerable narcissists fear and avoid situations where their insecurities might be exposed.
      • The CEO pressures the therapist to affirm his greatness, while the student fears the therapist will see her as inadequate.
    2. Emotional Reactions:
      • The CEO might react to confrontation with anger or dismissal, while the student might respond with shame or withdrawal.
    3. Defense Mechanisms:
      • Grandiose types externalize blame (“They’re the problem”), whereas vulnerable types internalize it (“I’m the problem”).

    Clinical Insights

    Both types present challenges in therapy:

    • Grandiose narcissists may struggle with self-reflection, requiring careful, non-confrontational approaches to expose vulnerabilities.
    • Vulnerable narcissists are often more willing to explore their insecurities but may require help managing their intense shame and self-doubt.